Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Mov Disord. 2010 Nov 15;25(15):2550-4. doi: 10.1002/mds.23319.
Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.
认知功能障碍是帕金森病（PD）最致残的非运动症状之一。一些认知缺陷被认为与多巴胺稳态异常有关。后者受儿茶酚-O-甲基转移酶（COMT）的影响，该酶可降解多巴胺。先前的研究表明 COMT val158met 功能多态性（SNP）与执行功能的测量之间存在关系。我们在荷兰综合医院的门诊诊所的一组 PD 患者中评估了这一假设。我们对 153 名早期 PD 患者进行了认知评估和 COMT 基因分型，以进行认知评估和 COMT 基因分型。我们的结果不支持 COMT val158met 基因型直接影响注意力和执行功能的神经心理学测量表现，但提示基因型可能与多巴胺能药物的使用相互作用，从而影响认知能力。
